No Debt On Balance SheetReported zero total debt materially lowers leverage and bankruptcy risk, preserving financing flexibility for R&D or partnerships. Over a multi‑month horizon this improves the company’s ability to secure non‑debt funding or negotiate better lending terms when needed.

Narrowing Net Loss TrendConsistent reduction in net losses suggests improving cost control or program efficiency. If sustained, this trend lengthens runway and lowers near‑term dilution pressure, indicating management has made structural adjustments that improve operational resilience.

Demonstrated Ability To Cut Cash BurnA marked drop in operating cash outflows shows management can materially reduce spending when required, enhancing short‑term runway and strategic optionality. This capability, if repeated, supports longer‑term program funding without immediate dilution.

Bears Say

Pre‑revenue Business ModelAbsence of operating revenue means value and sustainability hinge entirely on successful clinical progress, regulatory approvals, or partner deals. This structural reliance increases execution and financing risk and keeps cash needs elevated over months ahead.

Negative Shareholders' EquityNegative equity indicates accumulated losses have eroded the capital base, weakening balance‑sheet resilience. This reduces capacity to absorb shocks, can impair financing terms, and raises the likelihood of dilutive equity raises or constrained partner negotiations.

Persistent And Volatile Cash BurnOngoing negative and volatile cash flows create continuous reliance on external financing. That structural funding dependence increases dilution risk, can delay programs if capital markets tighten, and limits strategic flexibility over the next several months.

5J2 FAQ

What was Gabather AB’s price range in the past 12 months?

Gabather AB lowest stock price was €0.00 and its highest was €0.01 in the past 12 months.

What is Gabather AB’s market cap?

Gabather AB’s market cap is €2.15M.

When is Gabather AB’s upcoming earnings report date?

Gabather AB’s upcoming earnings report date is May 28, 2026 which is in 65 days.

How were Gabather AB’s earnings last quarter?

Gabather AB released its earnings results on Feb 26, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of €0 by €0.

Is Gabather AB overvalued?

According to Wall Street analysts Gabather AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Gabather AB pay dividends?

Gabather AB does not currently pay dividends.

What is Gabather AB’s EPS estimate?

Gabather AB’s EPS estimate is 0.

How many shares outstanding does Gabather AB have?

Gabather AB has 491,634,160 shares outstanding.

What happened to Gabather AB’s price movement after its last earnings report?

Gabather AB reported an EPS of €0 in its last earnings report, expectations of €0. Following the earnings report the stock price went down -19.231%.

Which hedge fund is a major shareholder of Gabather AB?

Currently, no hedge funds are holding shares in DE:5J2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gabather AB

Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.